"Mount Sinai Partners With AI Startup To Detect And Manage Kidney Disease" - Robin Schatz
Mount Sinai Health System on Friday announced an exclusive multiyear license and partnership with RenalytixAI, an artificial-intelligence startup with offices in New York and the UK. The goal is to reduce the $98 billion in preventable kidney disease and dialysis costs by predicting which patients are at the greatest risk of advanced kidney disease and taking steps to treat them early on. "The idea that we might be able to more proactively identify individuals at risk and coordinate their care in a true example of population health is very exciting," said Barbara Murphy, MD, dean of clinical integration and population health management and chair of the department of internal medicine at the Icahn School of Medicine at Mount Sinai, and chairwoman of the RenalytixAI scientific advisory board. "We're focusing on translating Mount Sinai discoveries into products that benefit patients," said Erik Lium, senior vice president at Mount Sinai Innovation Partners. "We're very pleased to be working with RenalytixAI to advance some of the technologies developed at Mount Sinai into more mature stages."
- Barbara Murphy, MD, Dean, Clinical Integration and Population Health, Chair, Department of Medicine, Icahn School of Medicine at Mount Sinai
- Erik Lium, PhD, Senior Vice President, Mount Sinai Innovation Partners